The combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with endocrine therapy (ET) has become the first-line treatment for advanced or recurrent Hormone Receptor (HR)-positive, HER2-negative (HR+/HER2-) breast cancer since around 2017. This evidence concerns the gene ERBB2 and breast carcinoma.